Annual ROE
-33.44%
-59.46%-228.52%
December 31, 2023
Summary
- As of February 7, 2025, CTNM annual return on equity is -33.44%, with the most recent change of -59.46% (-228.52%) on December 31, 2023.
- During the last 3 years, CTNM annual ROE has fallen by -74.35% (-181.74%).
- CTNM annual ROE is now -181.74% below its all-time high of 40.91%, reached on December 1, 2021.
Performance
CTNM ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-49.92%
+933.23%+94.92%
September 30, 2024
Summary
- As of February 7, 2025, CTNM quarterly return on equity is -49.92%, with the most recent change of +933.23% (+94.92%) on September 30, 2024.
- Over the past year, CTNM quarterly ROE has dropped by -14.72% (-41.82%).
- CTNM quarterly ROE is now -477.32% below its all-time high of 13.23%, reached on March 1, 2023.
Performance
CTNM Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
CTNM ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -228.5% | -41.8% |
| 3 y3 years | -181.7% | -719.4% |
| 5 y5 years | -181.7% | -719.4% |
CTNM ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -181.7% | at low | -477.3% | +94.9% |
| 5 y | 5-year | -181.7% | at low | -477.3% | +94.9% |
| alltime | all time | -181.7% | at low | -477.3% | +94.9% |
Contineum Therapeutics Class A ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -49.92%(-94.9%) |
| Jun 2024 | - | -983.15%(+3407.5%) |
| Mar 2024 | - | -28.03%(-20.4%) |
| Dec 2023 | -33.44% | -35.20%(+18.2%) |
| Sep 2023 | - | -29.77%(-5.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | -31.36%(-337.0%) |
| Mar 2023 | - | 13.23%(+64.1%) |
| Dec 2022 | 26.02%(-36.4%) | - |
| Dec 2022 | - | 8.06% |
| Dec 2021 | 40.91% | - |
FAQ
- What is Contineum Therapeutics Class A annual return on equity?
- What is the all time high annual ROE for Contineum Therapeutics Class A?
- What is Contineum Therapeutics Class A annual ROE year-on-year change?
- What is Contineum Therapeutics Class A quarterly return on equity?
- What is the all time high quarterly ROE for Contineum Therapeutics Class A?
- What is Contineum Therapeutics Class A quarterly ROE year-on-year change?
What is Contineum Therapeutics Class A annual return on equity?
The current annual ROE of CTNM is -33.44%
What is the all time high annual ROE for Contineum Therapeutics Class A?
Contineum Therapeutics Class A all-time high annual return on equity is 40.91%
What is Contineum Therapeutics Class A annual ROE year-on-year change?
Over the past year, CTNM annual return on equity has changed by -59.46% (-228.52%)
What is Contineum Therapeutics Class A quarterly return on equity?
The current quarterly ROE of CTNM is -49.92%
What is the all time high quarterly ROE for Contineum Therapeutics Class A?
Contineum Therapeutics Class A all-time high quarterly return on equity is 13.23%
What is Contineum Therapeutics Class A quarterly ROE year-on-year change?
Over the past year, CTNM quarterly return on equity has changed by -14.72% (-41.82%)